On September 19, the FDA approved pembrolizumab and berahyaluronidase alfa-pmph for subcutaneous injection for adult and pediatric (12 years and older) solid tumor indications approved for the intravenous formulation of pembrolizumab. 

For more information, read the FDA announcement and the Merck press release.

Posted on 9/24/2025